Stem Point Capital LP Avidity Biosciences, Inc. Transaction History
Stem Point Capital LP
- $334 Billion
- Q3 2024
A detailed history of Stem Point Capital LP transactions in Avidity Biosciences, Inc. stock. As of the latest transaction made, Stem Point Capital LP holds 75,000 shares of RNA stock, worth $2.17 Million. This represents 0.05% of its overall portfolio holdings.
Number of Shares
75,000Holding current value
$2.17 Million% of portfolio
0.05%Shares
0 transactions
Quarter | Operation | Price Per share | shares change | shares Held | SEC Form |
---|
Others Institutions Holding RNA
# of Institutions
253Shares Held
107MCall Options Held
224KPut Options Held
161K-
Price T Rowe Associates Inc Baltimore, MD10.6MShares$308 Million0.06% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.23MShares$267 Million0.01% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$249 Million0.01% of portfolio
-
Rtw Investments, LP New York, NY8.13MShares$235 Million5.95% of portfolio
-
Wellington Management Group LLP Boston, MA7.03MShares$203 Million0.06% of portfolio
About Avidity Biosciences, Inc.
- Ticker RNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 52,127,000
- Market Cap $1.51B
- Description
- Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic...